BMY•benzinga•
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
Summary
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 14, 2025 by benzinga